Download PDF
Deutsche Zeitschrift für Onkologie 2016; 48(03): 96-99
DOI: 10.1055/s-0042-113489
Forschung
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Innovationen in der Onkologie

Hans-Peter Lipp
Further Information

Publication History

Publication Date:
05 October 2016 (online)

    Permissions and Reprints

Zusammenfassung

Analysiert man die aktuellen Arzneimittelentwicklungen in der klinischen Onkologie, so fällt auf, dass nur noch wenige neue Zytostatika vorgestellt werden, während es neben den zielgerichtet wirksamen Tumortherapeutika vor allem die Checkpoint-Inhibitoren sind, bei denen in kurzer Zeit nicht nur relativ viele neue Wirkstoffe, son­dern auch weitergehende Anwendungsgebiete vorgestellt werden. Auch mit onkolytischen Viren wird die Reaktivierung spezifischer T-Lymphozyten verfolgt, sodass zum gegenwärtigen Zeitpunkt die Strategie der spezifisch wirksamen Immunmodulation die Diskussion zu innovativen Therapiestrategien beherrscht.

Summary

Current drug development in clinical oncology is primarily focused on targeted thera­peutic agents as well as checkpoint inhibitors whereas novel cytotoxic drugs appear to be of minor quantitative importance. Particularly, the strategies based on reactiva­tion of the specifically acting immune system including oncolytic viruses, dominate the ongoing discussion regarding innovative therapeutics.

Schlüsselwörter

Arzneimittelentwicklungen - Zytostatika - zielgerichtete Therapien - Checkpoint-Inhibitoren - spezifische Immunmodulation

Keywords

Drug developments - cytotoxic drugs - targeted therapeutics - checkpoint- inhibitors - specific immunomodulation
 

  • Literatur

  • 1 Agarwala SS. The role of intralesional therapies in melanoma. Oncology 2016; 30: 436-41
    PubMedSearch in Google Scholar
  • 2 Deeks ED. Venetoclax: first global approval. Drugs 2016; 76: 979-87
    CrossrefPubMedSearch in Google Scholar
  • 3 Ehab M, Elbaz M. Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer 2016; 17: 83-91
    PubMedSearch in Google Scholar
  • 4 Elias R, Morales J, Rehman Y, Khurshid H. Immune checkpoint inhibitors in older adults. Curr Oncol Rep 2016; 18: 47
    CrossrefPubMedSearch in Google Scholar
  • 5 Garcia-Manero G, Almeida A, Giagounidis A et al. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. BMC Hematol 2016; [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 6 Hochhaus A, O’Brien SG, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-61
    CrossrefPubMedSearch in Google Scholar
  • 7 Ur Rehmann SS, Lim K, Wang-Gillam A. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Rev Anticancer Ther 2016; 16: 485-92
    CrossrefPubMedSearch in Google Scholar
  • 8 Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2016; [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 9 Siu LL, Conley BA, Boerner S, LoRusso PM. Next-generation sequencing to guide clinical trials. Clin Cancer Res 2015; 21: 4536-44
    CrossrefPubMedSearch in Google Scholar
  • 10 Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016; 17: e254-62
    CrossrefPubMedSearch in Google Scholar